Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cingulate Inc. Warrants (CINGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: CINGW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -96.9% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.86 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -114.14% | Return on Equity (TTM) -358.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4237731 |
Shares Outstanding - | Shares Floating 4237731 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Cingulate Inc. Warrants
Company Overview
History and Background
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for attention deficit hyperactivity disorder (ADHD). The warrants represent the right to purchase shares of Cingulate Inc.'s common stock at a specified price.
Core Business Areas
- ADHD Therapeutics Development: Developing and commercializing new drug formulations to treat ADHD.
Leadership and Structure
Information on Cingulate Inc.'s leadership team and organizational structure can be found in their SEC filings and on their investor relations website. The company has a board of directors and an executive team responsible for the overall strategy and operations.
Top Products and Market Share
Key Offerings
- CTX-1301 (dexmethylphenidate): An investigational drug for the treatment of ADHD. Currently in clinical trials. Competitors include stimulant medications from companies like Teva (TEVA), Mallinckrodt (MNK), and Tris Pharma.
- CTX-1302 (dextroamphetamine): An investigational drug for the treatment of ADHD. Currently in clinical trials. Competitors include stimulant medications from companies like Teva (TEVA), Mallinckrodt (MNK), and Tris Pharma.
Market Dynamics
Industry Overview
The ADHD therapeutics market is characterized by established medications and growing demand for novel treatments with improved efficacy and safety profiles.
Positioning
Cingulate Inc. aims to differentiate itself through innovative drug formulations designed for improved patient outcomes.
Total Addressable Market (TAM)
The global ADHD market is projected to reach billions of dollars. Cingulate Inc. is positioned to capture a portion of this market with successful clinical trials and FDA approval.
Upturn SWOT Analysis
Strengths
- Novel drug formulations
- Experienced management team
- Proprietary technology
Weaknesses
- Limited operating history
- Dependence on clinical trial success
- Uncertain regulatory approval
Opportunities
- Growing ADHD market
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- TEVA
- MNK
- TRIS
Competitive Landscape
Cingulate faces intense competition from established pharmaceutical companies with marketed ADHD products. Cingulate's success depends on demonstrating a differentiated clinical profile.
Growth Trajectory and Initiatives
Historical Growth: Growth is currently measured by progress in clinical trials and partnerships.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and product launch. Analyst estimates depend on clinical outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for CTX-1301 and CTX-1302.
Summary
Cingulate Inc. is a development-stage biopharmaceutical company with potential in ADHD therapeutics, however it faces risks associated with clinical trials and regulatory approval. Its success depends on the clinical performance of its lead drug candidates. Cingulate needs to closely manage its cash flow and secure strategic partnerships. The market competition is intense and they must demonstrate that their products have clear advantages.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual financial circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cingulate Inc. Warrants
Exchange NASDAQ | Headquaters Kansas City, KS, United States | ||
IPO Launch date 2021-12-08 | Co-Founder, CEO & Chairman of the Board Dr. Shane J. Schaffer Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.cingulate.com |
Full time employees 13 | Website https://www.cingulate.com | ||
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.